 | Info Sheets |
| | | | | | | | | | | | | | | | | | | | | | | | |
 | Out- side |
| | | | |
|
| | | | |
Result : Searchterm 'T1 Weighted Image' found in 1 term [ ] and 17 definitions [ ], (+ 14 Boolean[ ] results
| previous 26 - 30 (of 32) nextResult Pages : [1] [2 3 4] [5 6 7] |  | |  | Searchterm 'T1 Weighted Image' was also found in the following services: | | | | |
|  |  |
| |
|
( FISP) A fast imaging sequence, which attempts to combine the signals observed separately in the FADE sequence, generally sensitive about magnetic susceptibility artifacts and imperfections in the gradient waveforms. Confusingly now often used to refer to a refocused FLASH type sequence. This sequence is very similar to FLASH, except that the spoiler pulse is eliminated. As a result, any transverse magnetization still present at the time of the next RF pulse is incorporated into the steady state.
FISP uses a RF pulse that alternates in sign.
Because there is still some remaining transverse magnetization at the time of the RF pulse, a RF pulse of a degree flips the spins less than a degree from the longitudinal axis.
With small flip angles, very little longitudinal magnetization is lost and the image contrast becomes almost independent of T1. Using a very short TE (with TR 20-50 ms, flip angle 30-45°) eliminates T2* effects, so that the images become proton density weighted. As the flip angle is increased, the contrast becomes increasingly dependent on T1 and T2*. It is in the domain of large flip angles and short TR that FISP exhibits vastly different contrast to FLASH type sequences.
Used for T1 orthopedic imaging, 3D MPR, cardiography and angiography. | |  | | | Further Reading: | Basics:
|
|
| |
|  | |  |  | |  | |  |  | |  |  | Searchterm 'T1 Weighted Image' was also found in the following services: | | | | |
|  |  |
| |
|
(Mn-DPDP) This agent, mangafodipir trisodium, is a hepatocyte specific MRI contrast agent. Manganese is very toxic, so it has to be chelated and put in the form of a vitamin B6 analog, which is taken up by normal hepatocytes to some extent.
Teslascan® was developed in the early 1980's, went through clinical trials in the early 1990's, and was approved in 1997. One problem with assessing the efficacy of this agent is the fact that the phase III trials finished in the early 1990's, and the techniques used for MR today are very different from the techniques used almost a decade ago.
This contrast agent shortens the T1 relaxation time. On T1 weighted pictures it makes a normal liver look brighter. Since metastases, for example, do not generally take up this agent, the contrast between the enhancing liver and the non-enhancing lesions will increase on T1 weighted pictures. It does not have much effect on T2 weighted images.
Drug Information and Specification T1, Predominantly positive enhancement PHARMACOKINETIC Hepatobiliary, pancreatic, adrenal DOSAGE 5 µmol/kg, 0.5 ml/kg PREPARATION Finished product DEVELOPMENT STAGE Approved PRESENTATION Vials of 100 ml DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT!
Distribution Information TERRITORY TRADE NAME DEVELOPMENT STAGE DISTRIBUTOR | |  | | • View the DATABASE results for 'Teslascan®' (4).
| | | | Further Reading: | | Basics:
|
|
News & More:
| |
| |
|  | |  |  | |  | |  |  |
|  | | |
|
| |
 | Look Ups |
| |